Valuation: Apogee Therapeutics, Inc.

Market Cap 10.07B 8.75B 8.17B 7.5B 14.14B 960B 14.39B 96.33B 37.73B 479B 37.82B 36.98B 1,579B P/E 2026 *
-31.1x
P/E 2027 * -24x
Enterprise Value 9.09B 7.9B 7.38B 6.77B 12.77B 866B 12.99B 86.96B 34.06B 432B 34.14B 33.39B 1,425B EV / Sales 2026 *
1,000x
EV / Sales 2027 * 746x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.05%
1 week-0.13%
Current month+0.01%
1 month+0.90%
3 months+66.08%
6 months+94.67%
Current year+77.68%
1 week 134.03
Extreme 134.03
134.35
1 month 133.13
Extreme 133.13
134.46
Current year 60.35
Extreme 60.35
134.46
1 year 34.34
Extreme 34.34
134.46
3 years 14.19
Extreme 14.19
134.46
5 years 14.19
Extreme 14.19
134.46
10 years 14.19
Extreme 14.19
134.46
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
24/7/26 Don

Chief Financial Officer

-15,000 0.0268%
14/7/26 Don

Chief Technology Officer

-8,000 0.0143%
10/7/26 Don

Chief Executive Officer

-75,046 0.1340%
Change 5-day change 1-year change 3-year change Capi.($)
+0.01%-0.13%+255.26%+534.99% 10.07B
+0.14%-0.14%-1.10%+13.47% 48.22B
-2.71%-2.99%+398.09%+472.12% 38.79B
-0.71%+9.45%+27.90%+7.89% 38.41B
-0.71%-3.72%+4.94%+52.45% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.66%-2.73%+35.50%+122.17% 16B
-0.19%-3.93% - - 16.05B
+1.86%+0.64%+3.64%+17.04% 13.53B
-3.15%-6.14%-4.82%-36.90% 12.22B
Average -0.43%-0.61%+81.23%+135.71% 25.74B
Weighted average by Cap. -0.33%+0.14%+83.30%+121.54%

Financials

2026 *2027 *
Net sales 9.09M 7.9M 7.38M 6.77M 12.77M 867M 12.99M 86.98M 34.06M 432M 34.15M 33.39M 1.43B 12.5M 10.86M 10.14M 9.31M 17.56M 1.19B 17.86M 120M 46.84M 594M 46.95M 45.91M 1.96B
Net income -318M -276M -258M -237M -446M -30.27B -454M -3.04B -1.19B -15.09B -1.19B -1.17B -49.78B -416M -362M -338M -310M -585M -39.69B -595M -3.98B -1.56B -19.79B -1.56B -1.53B -65.29B
Net Debt -980M -851M -795M -730M -1.38B -93.36B -1.4B -9.37B -3.67B -46.56B -3.68B -3.6B -154B -740M -643M -601M -551M -1.04B -70.56B -1.06B -7.08B -2.77B -35.18B -2.78B -2.72B -116B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
03/08/26 USD 134.11 +0.01% 1,059,851
31/07/26 USD 134.09 -0.16% 1,744,242
30/07/26 USD 134.30 +0.07% 840,599
29/07/26 USD 134.20 +0.02% 1,082,800
28/07/26 USD 134.17 -0.08% 949,701
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.11USD
Average target price
130.53USD
Spread / Average Target
-2.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock